ViraCyte Pipeline

A Diversified Pipeline to Meet Patient Needs

ViraCyte therapies serve a dire, unmet medical need using a highly-effective, natural, immune restorative approach. Clinical trials already demonstrate significant promise, with over 90% of patients responding to ViraCyte therapy, with good evidence of safety and tolerability. All ViraCyte products are actively being evaluated in advanced clinical trials to gain more information needed for eventual approval and widespread availability.